The Pharma Letter M&A roundup - September 2023

6 October 2023

Pharma's biggest companies were inactive during September's M&A market.

Just four deals were reported on by The Pharma Letter in total, a 66% reduction on the 12 of the previous month.

Perhaps the most interesting acquisition of September was Italy-based Alfasigma buying Intercept Pharmaceuticals (Nasdaq: ICPT), a US biopharma that once appeared to be in pole position to reach western markets with the first treatment for non-alcoholic steatohepatitis (NASH), but has since suffered numerous share-busting setbacks with its candidate obeticholic acid.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK